Next 10 |
home / stock / argnf / argnf news
2024-04-24 10:00:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio meaningfully beat the benchmark MSCI EAFE Index, as well as the seconda...
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART ® treatment April 16, 2024...
2024-04-10 12:50:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ...
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 1...
VYVGART ® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents first global approval for VYVGART in ITP March 26, 2024 7:00 AM CET Amsterdam, the Netherlands – a...
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term use of VYVGART ® and VYVGART ® Hytrulo in gMG patients March 7...
$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June 21, 2024 On track to report data from six Phase 2 proof-of-concept trials by end ...
Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART ® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Eu...
2024-02-18 03:45:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Fifth Avenue Growth Fund® (the Fund) was up 17.6% (Institutional Shares) in...
News, Short Squeeze, Breakout and More Instantly...
Argen X NV Company Name:
ARGNF Stock Symbol:
OTCMKTS Market:
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART ® treatment April 16, 2024...
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ...
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 1...